PT - JOURNAL ARTICLE AU - Pullano, Giulia AU - Domenico, Laura Di AU - Sabbatini, Chiara E AU - Valdano, Eugenio AU - Turbelin, Clément AU - Debin, Marion AU - Guerrisi, Caroline AU - Kengne-Kuetche, Charly AU - Souty, Cécile AU - Hanslik, Thomas AU - Blanchon, Thierry AU - Boëlle, Pierre-Yves AU - Figoni, Julie AU - Vaux, Sophie AU - Campèse, Christine AU - Bernard-Stoecklin, Sibylle AU - Colizza, Vittoria TI - Underdetection of COVID-19 cases in France in the exit phase following lockdown AID - 10.1101/2020.08.10.20171744 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.10.20171744 4099 - http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171744.short 4100 - http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171744.full AB - A novel testing policy was implemented in May in France to systematically screen potential COVID-19 infections and suppress local outbreaks while lifting lockdown restrictions. 20,736 virologically-confirmed cases were reported in mainland France from May 13, 2020 (week 20, end of lockdown) to June 28 (week 26). Accounting for missing data and the delay from symptom onset to confirmation test, this corresponds to 7,258 [95% CI 7,160-7,336] cases with symptom onset during this period, a likely underestimation of the real number. Using age-stratified transmission models parameterized to behavioral data and calibrated to regional hospital admissions, we estimated that 69,115 [58,072-77,449] COVID-19 symptomatic cases occurred, suggesting that 9 out of 10 cases with symptoms were not ascertained. Median detection rate increased from 7% [6-9]% to 31% [28-35]% over time, with regional estimates varying from 11% (Grand Est) to 78% (Normandy) by the end of June. Healthcare-seeking behavior in COVID-19 suspect cases remained low (31%) throughout the period. Model projections for the incidence of symptomatic cases (4.5 [3.9-5.0] per 100,000) were compatible with estimates integrating participatory and virological surveillance data, assuming all suspect cases consulted. Encouraging healthcare-seeking behavior and awareness in suspect cases is critical to improve detection. Substantially more aggressive and efficient testing with easier access is required to act as a pandemic-fighting tool. These elements should be considered in light of the currently observed resurgence of cases in France and other European countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by ANR project DATAREDUX (ANR-19-CE46-0008-03) and EVALCOVID-19 (ANR-20- 706 COVI-0007); EU H2020 grants MOOD (H2020-874850) and RECOVER (H2020-101003589); REACTing COVID-19 modeling and surveillance grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GrippeNet.fr/COVIDnet.fr was reviewed and approved by the French Advisory Committee for research on information treatment in the health sector (i.e. CCTIRS, authorization 11.565), and by the French National Commission on Informatics and Liberty (i.e. CNIL, authorization DR-2012-024) - the authorities ruling on all matters related to ethics, data, and privacy in the country.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available at the references cited.